Zydus Lifesciences Limited · NSE:ZYDUSLIFE
Zydus Lifesciences — Q2 FY25 Earnings Presentation
17 slides from Zydus Lifesciences's earnings presentation, Nov 12, 2024
Slide 1: Exchange filing cover letter for investor presentation
zyd Dedicated To Life November 12, 2024 Listing Department Code: 532321 BSE LIMITED P J Towers, Dalal Street, Mumbai-400001 Listing Department Code: ZYDUSLIFE NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, C/1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai-400051 Re: Investor Presentat
Slide 2: Earnings Presentation: Q2 & H1 FY25
zyd us Dedicated To Life Zydus Lifesciences Limited Earnings Presentation: Q2 & H1 FY25 12th November, 2024 1
Slide 3: Disclaimer and Safe Harbor Statement
Disclaimer and Safe Harbor Statement zyd~ Dedicated To Life • THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF ZYDUS LIFESCIENCES LIMITED OR ITS SUBSIDIARIES OR JOINT VENTURES (TOGETHER, THE “COMPANY”). The material that follows is a
Slide 4: Q2 FY25: At a Glance
Q2 FY25: At a Glance zyd~ Dedicated To Life Revenues from Highlights of Q2 FY25 R&D Operations Total revenues grew 20% YoY, led by growth across businesses. ~ ---- -- --- -- ----- -- --- -- ----- -- --- -- ----- -- --- -- ----- ' ❑ Rs. 52,370 mn Rs. 4,800 mn ❑ India branded formulations business pos
Slide 5: Key Financial Metrics (1/2)
Key Financial Metrics (1/2) zyd~ Total Revenues (Rs. mn) Gross Profit (Rs. mn) and Gross Margin % 66.3 % 67.4 % 70.9 % 74.4 % 71.9% 62,075 55,338 46,214 52,370 39,223 37,656 43,688 45,052 28,950 30,367 T T T Q2 FY24 Q3 FY24 Q4 FY24 Q1 FY25 Q2 FY25 Q2 FY24 Q3 FY24 Q4 FY24 Q1 FY25 Q2 FY25 Total R&D (R
Slide 6: Key Financial Metrics (2/2)
Key Financial Metrics (2/2) zyd~ PAT ex. Exceptional (Rs. mn) Organic Capex (Rs. mn) 14,199 3,014 3,017 11,823 2,162 2,137 2,126 9,112 8,007 7,896 T T T Q2 FY24 Q3 FY24 Q4 FY24 Q1 FY25 Q2 FY25 Q2 FY24 Q3 FY24 Q4 FY24 Q1 FY25 Q2 FY25 Net Cash (Rs. mn) Net Working Capital* (Rs. mn) 25,906 71,427 65,35
Slide 7: India Formulations business
India Formulations business zyd~ Dedicated To Life Sustained market outperformance led by strong volume uptake Highlights for the quarter India Formulations Sales (Rs. mn) Q2 FY25 Revenue ▪ Branded business grew faster than the market with Contribution 10% YoY growth. 14,273 13,806 13,758 14,569 13,
Slide 8: Consumer Wellness
Consumer Wellness zyd~ Dedicated To Life Strong volume uptake driven by robust demand across categories Highlights for the quarter Consumer Wellness Sales (Rs. mn) Q2 FY25 Revenue Contribution ▪ Growth was largely driven by strong 8.4% volume 8,366 7,755 growth. 4,352 4,875 ▪ Both the personal care
Slide 9: US Formulations business
US Formulations business zyd~ Dedicated To Life Base business volume expansion and new launches led to strong growth Highlights for the quarter US Formulations Sales (Rs. mn) Q2 FY25 Revenue Contribution ▪ Launched 4 new products. 30,929 25,235 24,168 ▪ Filed 8 ANDAs and received approval for 9 ANDA
Slide 10: International Markets Formulations business
International Markets Formulations business zyd~ Dedicated To Life Strong growth on the back of resilient demand across markets Highlights for the quarter IM Formulations Sales (Rs. mn) Q2 FY25 Revenue Contribution 5,389 ▪ Robust growth across key markets despite ongoing 4,960 5,309 4,937 political
Slide 11: Updates on Innovation (1/2)
Updates on Innovation (1/2) zyd~ Dedicated To Life NCE: Saroglitazar Magnesium • Data monitoring and follow-up is going on post the completion of patient recruitment for Phase II(b)/ III clinical trials for PBC indication and Phase II(b) clinical trials MASH indication for the US market. NCE: Usnofl
Slide 12: Updates on Innovation (2/2)
Updates on Innovation (2/2) zyd~ Dedicated To Life Biotech R&D • Completed patient recruitment for Phase III clinical trials for one of the biosimilars and follow-up has been completed. • Completed pre-clinical toxicity studies for one of the biosimilars and applied for clinical trials permission to
Slide 13: Other Updates
Other Updates zyd~ Dedicated To Life ▪ Forayed into animal free fermentation-based protein business by forming a JV with Perfect Day Inc. through acquisition of 50% stake in Sterling Biotech Ltd Venturing into (SBL). fermentation-based ▪ Setting-up a state-of-the-art manufacturing facility to produc
Slide 14: Zydus at a Glance
Zydus at a Glance zyd~ Dedicated To Life ~$2.35 bn Global Revenues1 5th Largest generic Co. in US in terms of prescription3 8 R&D Centers For NCE, APIs, Generics, Vaccines Biosimilars and Wellness products Among 1st Revenues from India Approved product for >35% In >55% of product Geography (Formulat
Slide 15: Consolidated Financial Performance (reported)
Consolidated Financial Performance (reported) zyd~ Dedicated To Life Q2 Q2 YoY Q1 QoQ H1 H1 YoY Rs. mn FY25 FY24 gr. FY25 gr. FY25 FY24 gr. Total Income from Ops. 52,370 43,688 19.9% 62,075 -15.6% 1,14,445 95,084 20.4% Gross Contribution (GC) 37,656 28,950 30.1% 46,214 -18.5% 83,870 63,602 31.9% Gro
Slide 16: Details of Exchange Rate Fluctuations
Details of Exchange Rate Fluctuations zyd~ Dedicated To Life II Q2 II Q2 II YoY H1 H1 YoY Rs. mn I I I I . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . i FY25 ..I.I .......... ......... FY24 .I.........
Slide 17: Thank you
Thank you For any queries, please contact Arvind Bothra Arvind.Bothra@zyduslife.com +91-22-62711905 For more information, please visit: www.zyduslife.com Registered Office: www.linkedin.com/company/zyduslife Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi C